<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392535</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000510112</org_study_id>
    <secondary_id>ICR-CTSU-CHHIP-2006-10007</secondary_id>
    <secondary_id>ISRCTN97182923</secondary_id>
    <secondary_id>EU-20646</secondary_id>
    <nct_id>NCT00392535</nct_id>
  </id_info>
  <brief_title>Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer</brief_title>
  <official_title>Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer: CHHIP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Cancer Research, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to
      the tumor may kill more tumor cells and cause less damage to normal tissue. It is not yet
      known which schedule of intensity-modulated radiation therapy is more effective in treating
      patients with prostate cancer.

      PURPOSE: This randomized phase III trial is studying the side effects of three schedules of
      intensity-modulated radiation therapy and compares how well they work in treating patients
      with localized prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety and efficacy of conventional vs hypofractionated high-dose
           intensity-modulated radiotherapy in patients with localized prostate cancer.

        -  Determine the side effects of these regimens in these patients.

        -  Determine whether hypofractionated radiotherapy schedules will improve the therapeutic
           ratio by either improving tumor control or reducing normal tissue side effects.

        -  Compare acute and late treatment-related gastrointestinal and urological toxicity in
           these patients.

        -  Determine different prostate-specific antigen-related endpoints for local failure and
           distant metastases.

        -  Extend the database of patients treated to escalated doses with dose-volume histograms
           (DVHs) of normal tissues at risk and relate these to common toxicity endpoints.

        -  Develop a model to estimate normal tissue complication probability (NTCP) of rectum and
           bladder for hypofractionated as well as conventional dose-escalated radiotherapy
           schedules.

      OUTLINE: This is a multicenter, randomized, pilot study. Patients are stratified according to
      risk of seminal vesicle involvement (low-risk vs moderate-risk or high-risk).

        -  Hormone therapy: Patients receive androgen-deprivation therapy comprising an injection
           of luteinizing hormone-releasing hormone (LHRH) agonist once monthly for 3-6 months and
           oral cyproterone acetate beginning the week before the first LHRH agonist injection and
           continuing for at least 2 weeks after each LHRH agonist injection. Within one week after
           the last LHRH agonist injection, patients proceed to radiotherapy.

        -  Radiotherapy: Patients are randomized to 1 of 3 treatment arms.

             -  Arm I: Patients undergo conventional high-dose intensity-modulated radiotherapy
                (IMRT) in 37 fractions over 7.5 weeks.

             -  Arm II: Patients undergo hypofractionated high-dose IMRT in 20 fractions over 4
                weeks.

             -  Arm III: Patients undergo hypofractionated high-dose IMRT in 19 fractions over 3.8
                weeks.

      In all arms, treatment continues in the absence of unacceptable toxicity.

      Quality of life is assessed periodically during study treatment.

      After completion of study treatment, patients are followed periodically for up to 15 years.

      Peer Reviewed and Funded or Endorsed by Cancer Research UK

      PROJECTED ACCRUAL: A total of 2,163 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2002</start_date>
  <primary_completion_date type="Anticipated">September 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Acute and late radiation-induced side effects</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Freedom from prostate cancer recurrence</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Acute and late radiation-induced side effects</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of metastases</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recommencement of hormonal treatment for disease occurrence</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause-specific and overall survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health economics</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Models of normal tissue and tumor control</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">2163</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyproterone acetate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>releasing hormone agonist therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>hypofractionated radiation therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>intensity-modulated radiation therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate, meeting the following
             criteria:

               -  Clinical stage T1b-T3a, N0, M0

               -  Locally confined disease

               -  Previously untreated disease

          -  Prostate-specific antigen (PSA) ≤ 30 ng/mL

          -  Estimated risk of seminal vesicle involvement &lt; 30%

               -  Estimated risk of seminal vesicle involvement is defined as PSA + ([Gleason score
                  - 6] x 10) (i.e., if Gleason score ≤ 6, then PSA must be ≤ 30 ng/mL; if Gleason
                  score = 7, then PSA must be &lt; 20 ng/mL; if Gleason score = 8, then PSA must be &lt;
                  10 ng/mL; if Gleason score = 9 or 10 patient is ineligible)

        PATIENT CHARACTERISTICS:

          -  WHO performance status 0 or 1

          -  Life expectancy &gt; 10 years (5 years for patients with poorly differentiated cancers)

          -  WBC &gt; 4,000/mm^3

          -  Hemoglobin &gt; 11g/dL

          -  Platelet count &gt; 100,000/mm^3

          -  No other active malignancy within the past 5 years except basal cell carcinoma

          -  No hip prosthesis or fixation that would interfere with standard radiation beam
             configuration

          -  No comorbid conditions likely to impact on the advisability of radical radiotherapy
             (e.g., previous inflammatory bowel disease, previous colorectal surgery, significant
             bladder instability, or urinary incontinence)

        PRIOR CONCURRENT THERAPY:

          -  No prior pelvic radiotherapy

          -  No prior radical prostatectomy

          -  No prior androgen-deprivation therapy

          -  No concurrent full anticoagulation therapy with warfarin or heparin
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David P. Dearnaley, MD, FRCP, FRCR</last_name>
    <role>Study Chair</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Basingstoke and North Hampshire NHS Foundation Trust</name>
      <address>
        <city>Basingstoke</city>
        <state>England</state>
        <zip>RG24 9NA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-125-631-4793</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sussex Cancer Centre at Royal Sussex County Hospital</name>
      <address>
        <city>Brighton</city>
        <state>England</state>
        <zip>BN2 5BF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Bloomfield, MD</last_name>
      <phone>44-1273-696-955 ext. 7686</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bristol Haematology and Oncology Centre</name>
      <address>
        <city>Bristol</city>
        <state>England</state>
        <zip>BS2 8ED</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-117-928-3074</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>West Suffolk Hospital</name>
      <address>
        <city>Bury St. Edmunds</city>
        <state>England</state>
        <zip>IP33 2QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1284-713-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Addenbrooke's Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>England</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Helen Patterson, MD</last_name>
      <phone>44-122324-5151 ext. 2523 and 2</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Halton Hospital</name>
      <address>
        <city>Cheshire</city>
        <state>England</state>
        <zip>WA7 2DA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1928-714-567</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Countess of Chester Hospital</name>
      <address>
        <city>Chester</city>
        <state>England</state>
        <zip>CH2 1UL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1244-365-000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Walsgrave Hospital</name>
      <address>
        <city>Coventry</city>
        <state>England</state>
        <zip>CV2 2DX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caroline Humber, MD</last_name>
      <phone>44-2476-696-7483</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <state>England</state>
        <zip>BN21 2UD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fiona McKinna, MD</last_name>
      <phone>44-12-7369-6955 ext. 4600</phone>
      <email>fiona.mckinna@bsuh.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Luke's Cancer Centre at Royal Surrey County Hospital</name>
      <address>
        <city>Guildford</city>
        <state>England</state>
        <zip>GU2 7XX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J. F. Money-Kyrle, MA, MBBS, MRCP, FRCR</last_name>
      <phone>44-1483-406-800</phone>
      <email>julian.money-kyrle@royalsurrey.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ipswich Hospital</name>
      <address>
        <city>Ipswich</city>
        <state>England</state>
        <zip>IP4 5PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christopher Scrase, MD</last_name>
      <phone>44-147-370-4177</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Bartholomew's Hospital</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>EC1A 7BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Wells, MD</last_name>
      <phone>44-207-601-8044</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - London</name>
      <address>
        <city>London</city>
        <state>England</state>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-20-7352-8171</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <state>England</state>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Logue</last_name>
      <phone>44-161-446-3407</phone>
      <email>john.logue@christie-tr.nwest.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clatterbridge Centre for Oncology</name>
      <address>
        <city>Merseyside</city>
        <state>England</state>
        <zip>CH63 4JY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Syndikus, MD</last_name>
      <phone>44-151-334-1155 ext. 4748</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Norfolk and Norwich University Hospital</name>
      <address>
        <city>Norwich</city>
        <state>England</state>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. J. Ostrowski</last_name>
      <phone>44-603-286-286</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whiston Hospital</name>
      <address>
        <city>Prescot Merseyside</city>
        <state>England</state>
        <zip>L35 5DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zafar Malik, MD</last_name>
      <phone>44-151-426-1600</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rosemere Cancer Centre at Royal Preston Hospital</name>
      <address>
        <city>Preston</city>
        <state>England</state>
        <zip>PR2 9HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alison Birtle, MD</last_name>
      <phone>44-177-252-2916</phone>
      <email>alison.birtle@lthtr.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Research Centre at Weston Park Hospital</name>
      <address>
        <city>Sheffield</city>
        <state>England</state>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine Ferguson, MD</last_name>
      <phone>44-114-226-5077</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southport and Formby District General Hospital</name>
      <address>
        <city>Southport</city>
        <state>England</state>
        <zip>PR8 6PN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chinnamani Eswar, MD</last_name>
      <phone>44-1704-547-471</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden - Surrey</name>
      <address>
        <city>Sutton</city>
        <state>England</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David P. Dearnaley, MD, FRCP, FRCR</last_name>
      <phone>44-20-8661-3271</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Warrington Hospital NHS Trust</name>
      <address>
        <city>Warrington</city>
        <state>England</state>
        <zip>WA5 1QG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1925-635-911</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Worthing Hospital</name>
      <address>
        <city>Worthing</city>
        <state>England</state>
        <zip>BN11 2DH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-1903-205-111</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital Trust Incorporating Belvoir Park Hospital</name>
      <address>
        <city>Belfast</city>
        <state>Northern Ireland</state>
        <zip>BT8 8JR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-2890-699-204</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beatson West of Scotland Cancer Centre</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Contact Person</last_name>
      <phone>44-141-211-2318</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Center at Velindre Hospital</name>
      <address>
        <city>Cardiff</city>
        <state>Wales</state>
        <zip>CF14 2TL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John Staffurth, MD</last_name>
      <phone>44-292-061-5888 ext. 6353</phone>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>South CP, Khoo VS, Naismith O, Norman A, Dearnaley DP. A comparison of treatment planning techniques used in two randomised UK external beam radiotherapy trials for localised prostate cancer. Clin Oncol (R Coll Radiol). 2008 Feb;20(1):15-21. Epub 2007 Dec 3.</citation>
    <PMID>18054471</PMID>
  </reference>
  <reference>
    <citation>van As N, South C, Naismith O, et al.: Radiotherapy planning in UK phase III trials of dose-escalated (MRC RT01) and high-dose hypofractionated radiotherapy (CHHIP) in prostate cancer. [Abstract] 2006 Prostate Cancer Symposium, February 24-26, 2006, San Francisco, CA. A-98, 2006.</citation>
  </reference>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <last_update_submitted>May 19, 2011</last_update_submitted>
  <last_update_submitted_qc>May 19, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2011</last_update_posted>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage IIB prostate cancer</keyword>
  <keyword>stage IIA prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Cyproterone</mesh_term>
    <mesh_term>Cyproterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

